Renalytix Gets FDA De Novo Marketing Authorization for KidneyIntelX.dkd
2023年6月30日 - 7:58AM
Dow Jones News
By Stephen Nakrosis
Renalytix said the Food and Drug Administration has granted De
Novo marketing authorization for the KidneyIntelX.dkd prognostic
test.
Renalytix said the authorization "affirms KidneyIntelX as a
first-in-class, artificial intelligence enabled prognostic testing
platform to guide care management for adults with type 2 diabetes
and early stage chronic (diabetic) kidney disease."
De Novo authorization provides a marketing pathway for novel
medical devices, the FDA said.
Renalytix also said it believes the authorization will lead to
increasing test adoption, expanding insurance coverage, and the
pursuit of additional international regulatory approvals.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 29, 2023 18:43 ET (22:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Renalytix (NASDAQ:RNLX)
過去 株価チャート
から 5 2024 まで 6 2024
Renalytix (NASDAQ:RNLX)
過去 株価チャート
から 6 2023 まで 6 2024
